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Abstract 
 
Despite its bad reputation in the mass media, cholesterol is an indispensable constituent 
of cellular membranes and vertebrate life. It is, however, also potentially lethal as it may 
accumulate in the arterial intima causing atherosclerosis or elsewhere in the body due to 
inherited conditions. Studying cholesterol in cells, and research on how the cell biology of 
cholesterol affects on system level is essential for a better understanding of the disease 
states associated with cholesterol and for the development of new therapies for these 
conditions. On its way to the cell, exogenous cholesterol traverses through endosomes, 
transport vesicles involved in internalizing material to cells, and needs to be transported 
out of this compartment. This endosomal pool of cholesterol is important for under-
standing both the common disorders of metabolism and the more rare hereditary disord-
ers of cholesterol metabolism.  
 
The study of cholesterol in cells has been hampered by the lack of bright fluorescent ste-
rol analogs that would resemble cholesterol enough to be used in cellular studies. In the 
first study of my thesis, we present a new sterol analog, Boron-Dipyrromethene (BODI-
PY)-cholesterol for visualizing sterols in living cells and organism. This fluorescent cho-
lesterol derivative is shown to behave similarly to cholesterol both by atomic scale com-
puter simulations and biochemical experiments. We characterize its localization inside 
different types of living cells and show that it can be used to study sterol trafficking in 
living organisms. 
 
Two sterol binding proteins associated with the endosomal membrane; the Niemann-Pick 
type C disease protein 1 (NPC1) and the Oxysterol Binding Protein Related Protein 1 
long isoform (ORP1L) are the subjects of the rest of this study. Sensing cholesterol on 
endosomes, transporting lipids away from this compartment and the effects these lipids 
play on cellular metabolism are considered.  
 
In the second study we characterize how the NPC1 protein affects lipid metabolism. We 
show that this cholesterol binding protein affects synthesis of triglycerides and that genet-
ic polymorphisms or a genetic defect in the NPC1 gene affect triglyceride on the whole 
body level. These effects take place via regulation of carbon fluxes to different lipid 
classes in cells.  
 
In the third part we characterize the effects of another endosomal sterol binding protein, 
ORP1L on the function and motility of endosomes. Specifically we elucidate how a muta-
tion in the ability of ORP1L to bind sterols affects its behavior in cells, and how a change 
in ORP1L levels in cells affects the localization, degradative capacity and motility of endo-
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somes. In addition we show that manipulation of ORP1L affect cholesterol balance also 
in macrophages, a cell type important for the development of atherosclerosis.  
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Review of the Literature 
 
1. Cholesterol in Cells 
 
The most important role of cholesterol is as a structural building block and a functional 
unit of cellular membranes. In addition, cholesterol is needed as a precursor for the syn-
thesis of steroid hormones, bile acids and vitamin D. Cholesterol is a very rigid, planar 
molecule (Figure 1.) and therefore brings rigidity, impermeability, viscosity and stiffness to 
the membrane. These characteristics are especially important for the outer membrane of 
cells, the plasma membrane, which functions as a barrier between the cell and its sur-
roundings. The plasma membrane also contains more cholesterol than other cellular 
membranes (Lange, 1991).  
 
Figure 1. Structure of cholesterol 
 
 
Cellular cholesterol levels are determined by cholesterol intake (from lipoprotein par-
ticles), cholesterol synthesis and cholesterol efflux. A lot of cholesterol is absorbed from 
the diet, but all nucleated cells are also capable of synthesizing cholesterol for their own 
needs. The central nervous system, however, does not utilize dietary cholesterol as lipo-
proteins do not cross the blood brain barrier. The cells of the central nervous system are 
thought to synthesize all the cholesterol the brain needs (Dietschy, 2009). Cholesterol 
cannot be broken down by our cells, and must therefore be effluxed out of cells and ex-
creted out of the body when not needed.  
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1.1. Cholesterol in Cellular Membranes 
 
The basic structure of biological membranes consists of a phospholipid bilayer. When the 
membrane contains large amounts of cholesterol and sphingolipids, as in the case of the 
plasma membrane, the so called lipid rafts are formed. Rafts are nano scale clusters of 
these rigid lipids that form functional domains on the membrane (Simons and Ikonen, 
1997; Simons and Gerl, 2010). Rafts are believed to swim around the more fluid “sea” of 
the phospholipid membrane. Rafts are important at least in membrane trafficking (Romer 
et al., 2010)  and signaling (Suzuki et al., 2007). For a broader survey of lipid raft functions 
in cells, see a recent review (Simons and Gerl, 2010).  
 
In addition to the plasma membrane, cholesterol can be found in other cellular compart-
ments in varying degrees (reviewed in (Ikonen, 2008)). The endoplasmic reticulum (ER) 
only contains ~1% of total cellular cholesterol (Lange, 1991), but some endosomal com-
partments (Möbius et al., 2003) and the trans-side of the Golgi complex (Coxey et al., 
1993) contain significant amounts of cholesterol, the specific amounts depending on the 
metabolic state of the cells (Coxey et al., 1993). The ER, normally poor in cholesterol, 
contains the homeostatic machinery for maintaining intracellular cholesterol levels (see 
section 1.2. “Metabolic Homeostasis of Cholesterol”). Due to its low cholesterol content, 
even small changes in cholesterol levels can be sensed, enabling the cell to respond to 
small changes in sterol levels (Radhakrishnan et al., 2008). Mitochondria are the site for 
steroid hormone synthesis and some cholesterol oxidation reactions, so cholesterol is ac-
tively transported also to mitochondria, especially in steroidogenic cells (Kallen et al., 
1998).  
 
Lysosomes in a steady state are cholesterol-poor (Möbius et al., 2003). Some compart-
ments, like multivesicular endosomes and the recycling compartment do contain larger 
amounts of cholesterol (Hao et al., 2002; Möbius et al., 2003). How much cholesterol re-
sides in a given compartment also depends greatly on the cell type and its homeostatic 
state. 
 
1.2. Metabolic Homeostasis of Cholesterol 
 
At high concentrations, cholesterol forms cholesterol crystals, which are toxic to cells. 
High concentrations of cholesterol can also harm cells e.g. by causing ER stress (Feng et 
al., 2003). Too little cholesterol is, however, also detrimental to cells. This is demonstrated 
in inherited defects of cholesterol synthesis (reviewed in (Porter, 2002)) where function of 
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the plasma membrane, functions of many sterol associated proteins, synthesis of sterol 
derivatives and signaling pathways are perturbed. This has led to the evolution of tightly 
regulated cholesterol balancing systems, best characterized in fibroblasts and hepatocytes 
(Brown and Goldstein, 2009).  
 
When cellular cholesterol levels decrease, cells respond by increasing cholesterol synthesis 
and by taking up more cholesterol as lipoprotein particles. All cells can synthesize choles-
terol from acetate, but many peripheral cells also take up Low Density Lipoproteins 
(LDL) by receptor mediated endocytosis, and use cholesterol contained in these particles. 
When cholesterol concentration in cells decrease, a protein complex in the ER senses this 
change and activates transcription of genes involved in acquiring more cholesterol, i.e. 
genes of cholesterol synthesis and uptake (Figure 2). The core part of this machinery and 
the actual transcription factor is called the Sterol Regulatory Element Binding Protein 2 or 
SREBP2. When sterol levels are low, SREBP2 is transported to the Golgi where it is 
cleaved to yield an active transcription factor that enters the nucleus and activate genes 
that have the Sterol Regulatory Element in their promoter (Wang et al., 1994). SREBP2 
itself is not, however, sensitive to the surrounding sterol levels. Instead, the scaffolding 
protein of SREBP2, the SREBP Cleavage Activating Protein (SCAP) has a Sterol Sensing 
Domain (SSD) that is believed to convey the sterol sensitivity of the system (Nohturfft et 
al., 2000). When sterol levels in the ER are sufficient, SCAP binds to yet another protein, 
Insig, which blocks the exit of the SREBP-SCAP complex from the ER and hence inhi-
bits transcription of genes needed for increasing cholesterol levels (Yang et al., 2002). 
When sterol levels decrease, the conformation of SCAP changes and it no longer binds 
Insig. This frees the SREBP-SCAP complex to be transported to the Golgi, where 
SREBP2 is cleaved to an active transcription factor. Another form of SREBP, SREBP1C 
is involved in the regulation of neutral lipid synthesis, but has less effect on cholesterol 
balance (Liang et al., 2002) (Figure 2). 
 
If, on the other hand, cholesterol levels in the cell are too high, another transcription fac-
tor system is activated, leading to elimination of cholesterol from cells (Venkateswaran et 
al., 2000). The main components of this system are the Liver X Receptors (LXRs). These 
are activated by several different oxysterols (Janowski et al., 1999), i.e. oxidized derivatives 
of cholesterol that form when cholesterol levels increase. LXRs form heterodimers with a 
Retinoid X Receptor (RXR) to activate transcription (Willy et al., 1995). LXR target genes 
include several ATP Binding Cassette (ABC) transporters such as ABC-A1 and ABC-G1 
transporting cholesterol out of cells, but also many genes necessary for eliminating choles-
terol from the body, such as genes involved in bile acid synthesis and secretion (Figure 2). 
LXR activation thus leads to elimination of cholesterol at both cellular and whole body 
level. In addition, LXRs also activate fatty acid and triglyceride synthesis, but the signific-
 ance of this somewhat paradoxical phenomenon has remained unclear. A more complete 
list of LXR targets and mechanism of function is presented in 
 
 
Figure 2. Transcriptional regulation of lipids
 
 
 
In addition to activating the LXR pathway, cells are
esterifying it with a fatty acid. These cholesteryl esters are generated by the ER resident 
protein Acyl-coenzyme A Cholesterol Acyltransferase
1970) and the esters are main
regulated by the transcriptional systems described above, but allosterically by cholesterol 
so that when abundant in the ER, cholesterol becomes
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 1 (ACAT1) (Stokke and Norum, 
ly stored in cytoplasmic lipid droplets. This enzyme is not 
 esterified (Chang et al., 1998)
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2. Cholesterol Trafficking in Cells  
 
Due to its high hydrophobicity, cholesterol does not dissolve in water, and therefore can-
not travel freely through the cytosol by aqueous diffusion. Cholesterol transport in cells 
may occur through several different mechanisms. It can travel along with cellular mem-
brane trafficking, it can be transported by cytosolic carrier proteins or it can move from 
membrane to membrane via membrane contact sites (Ikonen, 2008). There is evidence to 
support the existence of all three routes, and it is probable that all of these routes contri-
bute to the distribution of cholesterol.  
 
Intracellular membrane trafficking is a major means to transfer cargo in cells. In this 
process vesicles bud off from one membrane compartment (e.g. ER), travel to the target 
membrane (e.g. the Golgi complex) and fuse with it. Cargo can travel along inside the 
vesicle or in/on the vesicle membrane. Many membrane trafficking routes have been cha-
racterized in detail. In general, membrane trafficking needs machineries for vesicle bud-
ding from the donor membrane (e.g. coat proteins such as clathrin) (Kirchhausen, 2000), 
transport machineries (e.g. molecular motors) to travel from the original membrane to the 
target (Ross et al., 2008) and fusion machineries (e.g. the Soluble NSF Attachment Protein 
Receptor (SNARE) proteins) to fuse with the target membrane (Jahn and Scheller, 2006). 
Long range movement of membranes takes place via microtubules. Molecular motors 
exhibit the ability to walk along the microtubules, but are restricted in their directionality. 
One family of proteins called dyneins is responsible for transport towards the microtubule 
minus ends (towards the centrosome). Another family of proteins, kinesins, are responsi-
ble for transport towards the microtubule plus ends (towards the cell periphery) as in the 
case for endosomes (Loubery et al., 2008). Both proteins also need several accessory pro-
teins, such as dynactin, to function in cells. Plus and minus end directed movement of 
organelles is known to be coregulated and different motors are known to exist simulta-
neously on the same organelles (Loubery et al., 2008; Ross et al., 2008). Cholesterol does 
travel passively along with intracellular membrane trafficking. The transport of cholesterol 
does, however, seem to also depend on membrane trafficking, at least when exiting from 
endosomes (Hölttä-Vuori et al., 2000).  
 
Another possible way for cholesterol to move inside cells is via cytosolic carrier proteins. 
Several families of cytosolic sterol binding proteins could potentially bind cholesterol on 
one membrane and hand over the cholesterol molecule to the target membrane. These 
families include the Oxysterol Binding Protein (OSBP) Related Proteins (ORP), the Star-
related lipid transfer domain containing proteins (STARTs) and the Sterol Carrier Pro-
teins (SCPs). Of these, the ORPs are described in more detail under “ORP Family of Pro-
teins” and START and SCP family of proteins are more extensively covered in a recent 
review (Lev, 2010).  
 
11 
 
 
The third mode to transfer cholesterol from membrane to membrane is via membrane 
contact sites. These are locations in cells where membranes of two organelles come close 
together, but do not fuse or necessarily touch physically (Levine and Loewen, 2006). The 
physical closeness of the membranes increases the probability for lipids to transfer from 
one membrane to another, and this process may be aided by proteins localized to the con-
tact sites. This cholesterol transport route, however, has the least experimental evidence 
to support it (Lev, 2010).  
 
2.2. Endosomal Cholesterol Trafficking 
 
One of the trafficking routes of cholesterol is the endocytic transport of LDL particles to 
lysosomes. Endosomes constitute a membrane transport pathway starting at the plasma 
membrane and ending in lysosomes, where cargo is degraded (Saftig and Klumperman, 
2009). Endocytic cargo is first transported to early/sorting endosomes, then further into 
late endosomes and finally to lysosomes. In this endosomal progression the pH of the 
organelles gradually decreases and the outer endosomal membrane buds inwards forming 
internal membranes (Saftig and Klumperman, 2009). On light microscopy level it is diffi-
cult to separate late endosomes from lysosomes as they contain a lot of the same markers. 
These markers include Lysosome Associated Membrane Proteins (Lamps) and many en-
docytosed fluorescent markers (such as small molecular weight dextran used in this thesis) 
which reside in both compartments. The term endolysosome is used in this thesis to refer 
to late endosomes and lysosomes together. LDL particle bound to the LDL receptor at 
the plasma membrane is transported along this pathway to endolysosomes where the 
LDL-derived cholesteryl esters are hydrolyzed, followed by efflux of cholesterol to other 
cellular membranes (Ikonen, 2008).  
 
The transport of cholesterol out of endolysosomes appears to be slow (Schoer et al., 
2000) and to some extent depend on membrane trafficking (Hölttä-Vuori et al., 2000). In 
contrast, the transport of cholesterol from the ER to the plasma membrane (Urbani and 
Simoni, 1990; Heino et al., 2000) and from the plasma membrane to ER and lipid droplets 
(Raychaudhuri et al., 2006; Jansen et al., 2010) has been shown to be mostly independent 
of vesicular trafficking. Many disorders of endosomal function such as Niemann-Pick 
diseases (described below), Gaucher disease (Vaccaro et al., 2010)  and Mucolipidosis type 
IV (Soyombo et al., 2006) lead to accumulation of free cholesterol in endosomes. Reasons 
to why sterol transport in/from endolysosomes is so different from other cellular mem-
branes may include the highly glycosylated limiting membrane of lysosomes. This rigid 
membrane functions to protect the lysosomal outer membrane from degradation, isolat-
 
12 
 
ing the outer membrane from the lysosomal lumen and possibly affecting cholesterol mo-
bility.  
  
2.2.1. NPC Family of Proteins 
 
Niemann-Pick type C (NPC) disease (Online Mendelian Inheritance in Man (OMIM) IDs 
#257220 and #607625) is an autosomal recessive disorder characterized by accumulation 
of cholesterol and other membrane constituents in all tissues (Figure 3. reviewed in (Vani-
er, 2010)). The disease manifests itself most commonly as a neurodegerative disease lead-
ing to death often in late childhood. Mutations in either of the two causative genes NPC1 
(Carstea et al., 1997) or NPC2 (Naureckiene et al., 2000) lead to indistinguishable clinical 
and biochemical diseases. The major early finding of the disease was that NPC patient 
fibroblasts failed to respond to increased levels of LDL by increasing cholesterol esterifi-
cation (Pentchev et al., 1985). Control cells started to increasingly esterify cholesterol in 
order to limit the amount of cellular free cholesterol, in response to an increase in choles-
terol levels, but NPC cells were unable to accomplish this. Later it was shown that NPC 
cells are unable to suppress the biosynthesis of cholesterol (Liscum and Faust, 1987) and 
to generate oxysterols (Frolov et al., 2003) in response to LDL and are not able to efflux 
cholesterol out of the cells (Choi et al., 2003). It is therefore thought that NPC is primari-
ly a cholesterol retention disease and that NPC1 and NPC2 function in the mobilization 
of LDL-derived cholesterol (Wang et al., 2010). NPC1 is a member of the resistance-
nodulation-cell division (RND) permease family of proteins known to transport small 
hydrophobic molecules in bacteria, thereby causing multidrug resistance (Blair and Pid-
dock, 2009). Whether NPC1 could also function in pumping cholesterol or other small 
hydrophobic molecules, such as fatty acid (Davies et al., 2000) or sphingosine (Lloyd-
Evans et al., 2008) has long been discussed, without convincing results (Lloyd-Evans and 
Platt, 2010). 
 
NPC1 is a late endosomal protein containing 1278 amino acids and 13 putative trans-
membrane helices (Davies and Ioannou, 2000), a SSD (Carstea et al., 1997) and an N-
terminal cholesterol binding domain (Kwon et al., 2009). The SSD is homologous to the 
SSD of SCAP and of the rate limiting enzyme of cholesterol synthesis, 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG-CoA) reductase. Both of these proteins are regulated 
through the sterol binding by SSD. This domain is also shared by the morphogen recep-
tor Patched that is essential for animal development. The precise function of SSD in 
NPC1 and Patched is unknown, but mutations in the SSD render both proteins non-
functional (Watari et al., 1999; Martin et al., 2001).  
 
 NPC2 is a small soluble lysosomal protein
mology to NPC1. It is targeted to lysosomes via 
tor (Naureckiene et al., 2000)
plasma and bile (Klein et al., 2006)
cavity and is able to transfer cholesterol 
highest at low pH and in the presence of lipids typical for
(Cheruku et al., 2006), rendering the protein most active in late 
somes. NPC2 is the causative gene in only ~5% of all NPC cases and the rest are believed 
to be caused by NPC1. 
 
Once NPC2 has bound cholesterol, it can transfer it to
vitro.  A model of “hydrophobic han
el NPC2 binds cholesterol immediately after it has been released by Acid Lipase,
transfers it to NPC1, that is then able to place the cholesterol molecule on the lysosomal 
outer membrane (Wang et al., 2010)
ever, is only 17% of the total protein, so there is probably more to NPC1 function than 
known to date. 
 
Figure 3. Filipin staining of
small interfering RNA (siRNA) 
 
2.2.2. ORP Family of Proteins
 
OSBP related proteins (ORP
oxysterol binding domain (ORD; OSBP
to bind oxysterols. The crystals st
13 
 containing 132 amino acids 
the mannose-6-phosphate and its rece
 and is also secreted to many physiological fluids such as 
. The protein consists mostly of a cholesterol binding 
between membranes in vitro. 
 the lysosomal inner membranes 
endo
 the NPC1 N-terminal domain 
doff” was proposed based on these 
. The N-terminal domain used in these studies
 an epidermal carcinoma cells (A431) treated with
or siRNA against NPC1.  
 
s) are a family of 12 ORP proteins, all bearing a common 
-related ligand-binding domain)
ructure of the yeast OSH4 together with its sterol ligand 
 
that bears no ho-
p-
The transfer is 
somes and lyso-
in 
data. In this mod-
 and 
, how-
 control 
 
, enabling ORPs 
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has been resolved (Im et al., 2005). In addition to the ORD domain, most ORPs contain a 
pleckstrin homology domain that binds phosphatidylinositol lipids allowing ORPs to as-
sociate with membranes. Some ORPs also contain a FFAT (two phenylalanines in an 
acidic tract) domain involved in binding the ER resident Vesicle Associated Protein 
(VAP) (reviewed in (Yan and Olkkonen, 2008)). Distinct functions for several ORP pro-
teins have been described; OSBP functions in the integration of cholesterol balance and 
sphingomyelin synthesis (Perry and Ridgway, 2006), ORP1L has a role in motor recruit-
ment to endosomes (Johansson et al., 2007) and ORP2 regulates neutral lipid homeostasis 
(Hynynen et al., 2009) to mention but a few. The ORP family is conserved throughout the 
eukaryotic lineage. The yeast Saccharomyces cerevisiae has seven Oxysterol Binding Protein 
Homologs (OSH1-OSH7), indicating a fundamental role for these proteins in eukaryotic 
cell biology (Yan and Olkkonen, 2008).  
 
Whether ORPs transfer sterols from one membrane to another or function as sterol sen-
sors regulating other cellular processes has remained a matter of debate. In yeast it was 
shown that knocking out all of the seven yeast ORP homologues, impairs the transport of 
cholesterol (Raychaudhuri et al., 2006). No effect was, however, achieved by knocking 
down single ORP-homologues (Raychaudhuri et al., 2006). Some ORPs have also been 
shown to transfer cholesterol between liposomes in vitro (Ngo and Ridgway, 2009; Jansen 
et al., 2010) suggesting that at least some ORPs may transfer cholesterol between mem-
branes also in vivo. Whether cholesterol transport is the physiological role of mammalian 
ORPs, remains to be elucidated. 
 
ORP1L (ORP1 Long isoform), the ORP family member studied in this thesis is a late 
endosomal protein needed for normal perinuclear localization of late endosomes (Johans-
son et al 2007). It is the longer product of the ORP1 gene, which also gives rise to ORP1S 
(ORP1 Short isoform). ORP1L and ORP1S have different intracellular localizations and 
different tissue distributions, indicating diverging functions (Johansson et al., 2003). 
ORP1L forms a complex with Rab7, its effector RILP and dynein, driving the minus-end 
directed movement of late endosomes (Johansson et al 2007). ORP1L has also been 
shown be involved in the development of atherosclerotic lesions in vivo (Yan et al 2007). 
 
2.3. Uptake of Cholesterol into Cells 
 
When cells need cholesterol, they can acquire more by de novo synthesis, or by taking up 
cholesterol from various lipoprotein particles that serve as cholesterol donors to cells. 
Most peripheral cells take up cholesterol by receptor mediated endocytosis of LDL-
particles. The internalization of LDL starts when the major protein of LDL-particles, apo-
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lipoprotein B (ApoB) binds to cell surface LDL Receptor (LDLR) which triggers interna-
lization of this complex (Ho et al., 1976). The complex is endocytosed in clathrin coated 
pits and vesicles, and transported to early endosomes. In early endosomes the LDLR is 
released and is ready to recycle back to the plasma membrane via endocytic recycling 
pathways. The LDL particle is transported along the endocytic pathway to late endosomes 
and lysosomes, where the enzyme acid lipase hydrolyses the cholesteryl ester molecules to 
yield free cholesterol and free fatty acids (Ikonen, 2008).  How exactly cholesterol then 
leaves the endosomal system has remained unclear, except that NPC1 and NPC2 are 
probably involved in the placing of cholesterol to the lysosomal outer membrane.  
 
Special cell types: hepatocytes, macrophages and steroidogenic cells can take up chole-
steryl esters from High Density Lipoprotein (HDL) particles via scavenger receptor B1 
through selective lipid uptake where the cholesteryl ester molecules enters the cell, but the 
protein does not (Acton et al., 1996). Scavenger Receptor B1 is also used by macrophages 
in the uptake of LDL particles modified in the arterial intima. These modified particles are 
no longer recognized by LDLR (this process is described in more detail under “Role of 
macrophages in atherosclerosis”). A special case is also presented by enterocytes that are 
able to absorb diet-derived cholesterol from bile salt micelles in the gut lumen. 
 
2.4. Secretion of Cholesterol from Cells 
 
Just as cholesterol cannot freely move through the cytosol, it also cannot freely move in 
the circulation. Lipoproteins have evolved to transport cholesterol and other lipids from 
one tissue to another; to transport diet and liver-derived lipids to peripheral cells and cho-
lesterol from peripheral cells to the liver. Lipoproteins are droplets of neutral lipids (rang-
ing from 5-500nm) surrounded by a monolayer of phospholipids, free cholesterol, and an 
apolipoprotein (Figure 4). 
 
The cycle of cholesterol in lipoproteins starts in enterocytes that pack diet-derived lipids 
into chylomicron particles and secrete the particles into the lymph. Chylomicrons consist 
mostly of triglycerides. Most of this triglyceride is hydrolyzed by endothelial lipase and 
stored in the adipose tissue and the chylomicron remnants are taken up by the liver. The 
liver can use the cholesterol derived from chylomicron remnants for its own needs, store 
it, or pack it further in Very Low Density Lipoprotein (VLDL) particles. These particles 
are again secreted into the circulation. The triglyceride in VLDL particles is hydrolyzed to 
yield free fatty acids by members of the lipase-family proteins in the capillary endothelium 
(Hasham and Pillarisetti, 2006). What remains after this process is the LDL particle. Peri-
pheral cells can take up these particles and use the cholesterol in them as their cholesterol 
 source, but the majority of LDL is taken up to the liver 
reverse cholesterol transport pathway starts when the peripheral cells have more chole
terol than they need. This cholesterol is secreted into circulating HDL particles that are 
taken up by the liver which is able to secrete cholesterol to the bile and out of the system. 
For long it was believed that the liver is the only organ capable of secreting cholesterol 
out of the body, but it has been recently shown that the gut also contributes to feca
lesterol excretion (van der Velde et al., 2007)
 
Figure 4 . Common lipoproteins.
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acyltransferase (LCAT), a protein associated with HDL. As cholesterol accumulates on 
the ApoAI it becomes a spherical, mature HDL particle (Zannis et al., 2006). The secre-
tion of cholesterol to lipid-poor ApoAI and mature HDL happens via several plasma 
membrane cholesterol transporters of the ATP Binding Cassette (ABC) family (Cavelier 
et al., 2006). The most studied one of these is ABCA1 (ATP Binding Cassette transporter 
A1). The absence of functional ABCA1 causes Tangier disease that is characterized by a 
lack of HDL particles (Brooks-Wilson et al., 1999). ABCA1 mediated cholesterol efflux 
takes place on the plasma membrane and possibly in endosomes after endocytosis of 
ApoAI (Chen et al., 2005b), but the exact localization of cholesterol transfer to ApoAI 
remains debated (Kang et al., 2010) (Figure 5). ABCA1 prefers to efflux cholesterol to 
lipid-poor ApoAI and ABCG1 transfers cholesterol to the more mature, spherical HDL 
(Wang et al., 2004). The precise molecular mechanism of lipid transfer by these proteins 
remains to be elucidated.  
 
3. Studying Cholesterol Trafficking in Cells 
 
A major obstacle in studying intracellular cholesterol transport has been the lack of good 
methods. The interest in lipid cell biology has been rather low until the 21st century, and 
(cell biological) lipid methodology has therefore developed slowly. Lipids were long con-
sidered to be merely a source of energy and an inactive layer on the cell surface. With the 
emergence of the raft theory (Simons and Ikonen, 1997), increasing knowledge on athe-
rosclerosis, and new connections between lipids and other diseases, such as Alzheimer’s 
disease (Corder et al., 1993), the field of lipid research is gaining increasing interest. This 
is, to the benefit of a lipid scientist, also leading to new advances in technology in the 
field.  
 
Several challenges are ahead when one takes up the analysis of lipids; they cannot be 
chemically fixed, they easily oxidize during sample preparation if not handled correctly 
and their analytical methods are painstaking and involve many hazardous organic solvents. 
These difficulties have led to conflicting results and many unanswered questions. To 
overcome these handicaps, several different methodologies need to be used in parallel, to 
produce reliable results. 
 
3.1. Biochemical Methods to Study Cholesterol 
 
Cholesterol and other lipids can be biochemically separated from other organic matter by 
using chemical extraction by organic solvents and from each other by using chromato-
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graphic separation. For cholesterol this procedure is relatively easy as it can be separated 
from other cellular lipids by Thin Layer Chromatography (TLC). This method, however, 
does not separate cholesterol from its closest precursor sterols. However, in most cases 
cholesterol constitutes the absolute majority of sterols, and the precursors may often be 
ignored. For precise analysis of many other lipids, more sophisticated analysis such as 
mass spectrometry needs to be used.    
 
To study specific pools of cholesterol (or other lipids) one can use radioactively labeled 
lipids or lipid precursors and feed them to cells. The kinetics of metabolism and to some 
extent also transport can then be calculated from the results. While precise information 
about metabolism can be achieved using these methods, it should be carefully considered 
how the radioactive tracer is fed to the cells – the only physiological way for exogenous 
cholesterol to enter most cells is via lipoprotein particles.  
 
While radioactive cholesterol can help elucidate metabolism of cholesterol very accurately, 
less information can be drawn about its transport. To analyze where radioactive choles-
terol was transported to during the experiment, one must separate cellular compartments 
biochemically. This is most often done with density gradient ultracentrifugation where 
different compartments separate according to their density e.g. on a sucrose matrix. Cho-
lesterol can, however, move between compartments during sample preparation and the 
presence of cholesterol in a certain compartment in a biochemical experiment is not a 
guarantee that it has been transported there physiologically. Alternatively, the localization 
of radioactive cholesterol can be deduced from enzymatic processes. If, for example, ra-
dioactive cholesterol is esterified, it must have reached the ER where the esterification 
takes place. Esterification cannot, however, be used as an absolute measure of transport, 
as not all cholesterol transported to the ER is esterified (Jansen et al., 2010). Plasma 
membrane localized cholesterol can be determined by extracting cholesterol by methyl-?-
cyclodextrin (Pörn and Slotte, 1995; Heino et al., 2000) or by oxidizing cell surface choles-
terol after fixation of cells (Lange, 1991). Methyl-?-cyclodextrin was, however, recently 
shown to be internalized to cells by endocytosis, and may also extract cholesterol therein 
(Rosenbaum et al., 2010). 
 
Sterol binding and transfer by sterol binding proteins can be studied in vitro. A sterol bind-
ing protein can extract cholesterol from unilamellar vesicles (Ngo and Ridgway, 2009). 
Furthermore, the efficacy of a potent sterol transporter can be studied in a similar system 
where one pool of vesicles contains radioactive lipid and the other does not (Jansen et al., 
2010). These methods, however, apply preferentially to soluble proteins as membrane 
proteins cannot easily be inserted into liposomes. Protein binding to cholesterol in vivo can 
be studied using photocholesterol (7,7-azocholestanol) that is first incorporated into living 
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cells. This method makes it possible to study sterol binding of membrane protein such as 
NPC1 (Ohgami et al., 2004)  and MLN64 (Hölttä-Vuori et al., 2005).  
3.2. Imaging Methods to Study Cholesterol 
 
While biochemical methods cannot provide high resolution data about cholesterol locali-
zation in cells, methods using microscopy do this much more precisely. Cholesterol itself 
cannot, however, be imaged with traditional microscopy. One has to rely on either mole-
cules that bind cholesterol or on using fluorescent cholesterol analogs that behave similar-
ly to the natural lipid (Table 1).  
 
Table 1. Fluorescent compounds to study cholesterol localization in cells. (modified from 
(Ikonen and Hölttä-Vuori, 2004)). EM= Electron microscopy. 
 
Compound Charasteristics Living 
Cells? 
EM? References 
Filipin Fluorescent  
antibiotic 
No Yes (Linder et al., 
2007) 
?-toxin Derived from 
Clostridium   per-
fringens toxin 
perfringolysin-O 
No Yes (Möbius et al., 
2003; Sugii et 
al., 2003) 
Dehydroergosterol 
(DHE) 
A yeast natural 
sterol 
Yes No (Mukherjee et 
al., 1998; Hao 
et al., 2002) 
Dansyl             
cholestanol 
A cholesterol 
with a fluores-
cent dansyl-
group on posi-
tion 6  
Yes Possible but 
no reported 
so far 
(Wiegand et al., 
2003) 
NBD-cholesterols Several          
conjugates of 
NBD and       
cholesterol 
Yes Possible but 
no reported 
so far 
(Alecio et al., 
1982) 
 
 
The most widely used cholesterol staining agent is an antibiotic named filipin (Drabi-
kowski et al., 1973) that binds covalently to cholesterol 3’-OH group and is intrinsically 
fluorescent. Because of its antibiotic properties, it cannot, however, be used in living cells 
as while binding to cholesterol it perforates membranes. Filipin is considered to be a ra-
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ther faithful indicator of cholesterol distribution in cells, albeit it recognizes other 3’-
hydroxylated sterols in addition to cholesterol. As cholesterol comprises the majority of 
sterols in cells, the lack of specificity may often be ignored. Potential problems in using 
filipin include fixation of cells using paraformaldehyde which does not fix cholesterol. 
One cannot therefore be sure that cholesterol did not move from its original position 
during sample preparation. The binding of filipin to cholesterol may also be dependent on 
the membrane environment of cholesterol (Blau and Bittman, 1977). ?-toxin is another 
molecule that binds to cholesterol. It can be fluorescently labeled and can therefore be 
used as a marker for cholesterol (Möbius et al., 2003). It does not, however, penetrate the 
cells so it also cannot be used for living cells (Table 1). 
 
The other alternative is to use cholesterol-mimicking fluorescent tracers. The advantage in 
using fluorescent sterols is that they do not require fixation of cells and enable the follow 
up of sterol trafficking in living cells. The use of fluorescent sterols is discussed in more 
detail in the Results part of this book. 
 
4. Metabolic Diseases Affected By Endosomal Cholesterol 
 
Consuming excess amounts of lipid and cholesterol has led to the emergence of metabolic 
diseases in the western world. The most commonly known of these is atherosclerosis, 
caused by the retention of modified lipoproteins in the arterial intima, but atherosclerosis 
is often a part of a more complex disorder; the metabolic syndrome. Metabolic syndrome 
is characterized by central obesity, dyslipidemia and insulin resistance and creates a risk 
for developing diabetes and cardiovascular disease.   
 
4.1. Role of Hepatocytes in Metabolic Disease 
 
The liver is the major logistic station in cholesterol homeostasis at the whole body level. 
Modern western diet contains approximately 400mg cholesterol per day, and our bodies 
produce an additional 10mg/kg/day (Dietschy et al., 1993). Diet-derived cholesterol is 
transported to the liver in chylomicrons, and the liver is also responsible for most of cho-
lesterol synthesizes (outside the central nervous system). The liver also converts choles-
terol to bile acids and secretes bile acids and cholesterol into the gall bladder from where 
cholesterol eventually ends up in the small intestine and is excreted out of the body. Some 
of the cholesterol is reabsorbed back to the enterocytes and cycle back to the liver, con-
tributing to the enterohepatic cycle.  
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The liver is severely affected by excess consumption of lipid due to its central role in lipid 
metabolism. As natural selection has led to a system optimizing usage of energy and cho-
lesterol, the liver is not equipped to function with this kind of excess. Three things there-
fore happen; 1) cholesterol is secreted into bile in excess leading to cholesterol crystalliza-
tion in the gall bladder creating gall stones, 2) increasing storage of cholesterol and other 
lipid in the liver causing nonalcoholic fatty liver disease and rendering the liver insulin 
resistant (Seppälä-Lindroos et al., 2002) and 3) increased secretion of cholesterol and oth-
er lipids in VLDL particles (Adiels et al., 2006), leading to increased circulating LDL cho-
lesterol.  
 
Increased cholesterol leads to increased LXR activation causing increased hepatic de novo 
lipogenesis. Hepatocytes receive lipid from the diet, but also from the adipose tissue and 
from the so called “spill over pathway” where peripheral tissues are not able to receive all 
of the lipoprotein-derived fatty acids and this lipid ends up in the liver (Donnelly et al., 
2005). This lipid is stored in hepatic lipid droplets.  
 
4.2. Role of Macrophages in Atherosclerosis 
 
Atherosclerosis is a widely studied disease where excessive consumption of cholesterol is 
considered to be the major contributor. Excess dietary cholesterol, together with de novo 
synthesized cholesterol lead to surplus LDL in the circulation. Circulating LDL passes 
through the endothelium to reach target tissues that use LDL.  In the arterial intima, how-
ever, the internal elastic lamina prevents LDL particles from reaching the underlying tis-
sue (Smith, 1990). LDL therefore becomes trapped in the intima. These LDL particles get 
oxidized and further modified by resident enzymes and aggregate. Accumulating choles-
terol in the intima attracts macrophages that try to clear out this cholesterol (Tabas et al., 
2007). While failing at this task the macrophages internalize toxic amounts of cholesterol, 
store this cholesterol in their lipid droplets and become so called “foam cells”. These 
foam cells attract more immune cells and eventually die by apoptosis or necrosis, contri-
buting to the accumulation of debris in the intima. As this process proceeds over decades 
the intima thickens, develops a necrotic core consisting of cholesterol and dead cells. 
These atherosclerotic plaques may eventually rupture causing a heart attack or stroke.  
 
As is evident from the above description, macrophages play a key role in the development 
of atherosclerosis. While lowering circulating LDL is the main clinical target in atheroscle-
rosis management, pharmacological modifications of macrophage function are attracting 
increasing interest (Tabas et al., 2007). Macrophages are able to internalize modified lipo-
proteins found in atherosclerotic lesions very efficiently and very efficiently metabolize 
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this cholesterol and store it in lipid droplets. Higher levels of HDL are associated with 
smaller risk of atherosclerosis (Gordon et al., 1977), presumably because of the ability of 
HDL to enhance reverse cholesterol transport, i.e. cholesterol transport from macrophag-
es to the liver.  
 
Uptake of cholesterol is somewhat different in macrophages compared to other peripher-
al cells, as they are able to endocytose not only native LDL, but also oxidatively modified 
and aggregated LDL. The Scavenger Receptor B1 is mostly responsible for this uptake 
(Vainio and Ikonen, 2003). The LDLR is downregulated when cellular cholesterol levels 
increase (through a decrease in SREBP signaling), which prevents excessive accumulation 
of cholesterol in most cells. The SR-B1, however, is not downregulated in a similar man-
ner, but the macrophages internalize toxic amounts of cholesterol eventually leading to 
apoptosis (Vainio and Ikonen, 2003).  Macrophage cholesterol efflux is therefore a highly 
studied subject as enhancement of this efflux could decrease the advancement of atheros-
clerosis.  
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Aims of the Study 
 
This study aimed to shed light on how endosomal cholesterol and endosomal cholesterol 
binding proteins NPC1 and ORP1L affect biological processes on the cellular and whole 
body level. The individual aims of the three studies making up this thesis are listed below: 
 
I) We aimed to analyze whether a new fluorescent sterol analog, BODIPY-cholesterol  
would be suitable for visualizing cholesterol in living cells and organisms and to bring a 
new tool to the cholesterol field. The chemical synthesis and physical behavior of BODI-
PY-cholesterol has been reported (Li et al., 2006) making it an interesting candidate to be 
used for visualizing cholesterol.  
 
II) The aim of the second study was to characterize the interplay between Niemann-Pick 
type C disease and triglyceride homeostasis. This is a so far unexplored area, but receives 
increasing interest as our knowledge of the integration of metabolic pathways increases. 
In this study we analyzed the effects of common polymorphisms in the NPC1 gene on 
serum lipids at the population level and lipid metabolism in the liver and hepatocytes of 
Npc1+/+ and Npc1-/- mice. 
 
III) The aim of the third study was to characterize how ORP1L and its sterol binding sta-
tus affect endosomal processing and motility. It has been previously shown that this pro-
tein is involved in endosomal motor recruitment and localization and that it is involved in 
the development of atherosclerotic lesions. This study aimed at integrating previous cell 
biological findings with further characterization of the cell biology and effects of ORP1L 
in macrophages.  
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5. Materials and Methods 
 
5.1. Animal Work 
 
The Npc1-/- mouse has a spontaneous mutation in its Npc1 gene, and the mouse model 
was characterized already in 1980s (Miyawaki et al., 1982). The animals were maintained 
and used for experiments according to the guidelines of the institutional animal care and 
use committee. They were maintained on a chow diet (Altromin 1320) in standard condi-
tions. Roughly equal amounts of female and male mice were used as the results were simi-
lar in both genotypes, except in work II Figure 5 where only male mice were used.  
 
Primary mouse hepatocytes were isolated using the collagenase perfusion system (Smets 
et al., 2002). The mice were anesthesized using Mebunat 60mg/kg. The inferior vena cava 
was cannulated, the portal vein of the liver was sectioned and Earles balanced Salt solu-
tion (EBSS) with 0,5mM EGTA and 10mM Hepes, excluding Ca2+ and Mg2+ was flowed 
through the liver at 5ml/minute. After 6 minutes, the solution was changed into EBSS 
including Ca2+ and  Mg2+ and this was flowed through the liver for 3 minutes. Finally, 
EBSS including collagenase was allowed to flow through the liver for approximately 6 
minutes to collapse the liver macrostructure. The collapsed liver was then filtered through 
a 100µm nylon mesh to separate cells. The hepatocytes were washed 3-5 times with 
DMEM containing 10% Fetal Bovine Serum (FBS), 2mM glutamine, 100U/ml penicillin 
and 100µg/ml streptomycin and 10mM Hepes and plated on cell culture dishes coated 
with gelatin. One million cells were plated on a Ø 6 cm dishes and 500 000 cells on Ø 
3.5cm dishes. Hepatocytes were maintained in culture for no more than 24 hours. 
 
5.2. Cell Culture and Transfection 
 
Wild Type (WT) Chinese Hamster Ovary (CHO), M12 (Millard et al., 2000), and M19 
(Hasan et al., 1994) cells were cultured in DMEM supplemented with 5% FBS, 2mM glu-
tamine, 100U/ml penicillin and 100µg/ml streptomycin. HeLa cells were cultured similar-
ly, except with 10% FBS. Raw264.7 cells were cultured as HeLa cells but including 10mM 
Hepes. Cell culture plastics were from Gibco or Sarstedt. Lipoprotein deficient serum 
(LPDS) was prepared by sequential KBr gradient ultracentrifugation of FBS (Krieger, 
1986). 
 
cDNA constructs were transfected to cells using LipoFectamine2000. For 0.5ml of cells, 
3µl LipoFectamin2000 (Invitrogen) was diluted in 100µl and 1µg DNA was diluted in 
100µl OPTIMEM and these complexes were incubated for 5 minutes. The LipoFecta-
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mine2000 solution was then added to the DNA solution and this was incubated further 
for 15 minutes. The transfection complex was then added to freshly divided cells in anti-
biotic free medium. The complex was removed after 4 hours and the overexpressing cells 
were analyzed the following day. For transfections with small interfering RNAs (siRNA) 
on Ø 3.5cm dishes in 1ml of culture medium, 20pmol of the siRNA duplex and 6µl of the 
HiPerFect reagent (Qiagen) were diluted in 100µl OPTIMEM and the complex was incu-
bated 5-10 minutes. The complex was then added to cells cultured in complete medium. 
The cells were analyzed after 3 days of siRNA transfection.  
 
5.3. Labeling of Cells with Fluorescent Probes 
 
BODIPY-cholesterol was fed to cells dissolved in DMSO (dimethyl sulphoxide) 0.5µM in 
LPDS overnight to two days. Alternatively, BODIPY-cholesterol was complexed with 
methyl-?-cyclodextrin with a final calculated concentration of 25µg/ml BODIPY-
cholesterol (with molar ratio of sterol/cyclodextrin 1/10 as in (Leppimäki et al., 2000)). 
Rhodamine-dextran was fed to cells overnight at 1mg/ml and Alexa 568-dextran over-
night at 50µg/ml concentration, both were from Molecular Probes. Alexa 568-transferrin 
(Molecular probes) was fed to cells at 50µg/ml for 30 minutes. Prior to transferrin labe-
ling the cells were starved in serum free medium for 1 hour. Macrophages were labeled 
with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine-perchlorate labeled acetylated 
LDL (DiI-acLDL) in serum free medium at 50µg/ml for 1 hour.  
 
5.4. Labeling of Cells with Radioactive Probes 
 
Cells were labeled with [3H]cholesterol 1µCi/ml overnight (Raw264.7 macrophages) or 
two days (CHO cells). [3H]oleate was fed to cells in a complex with BSA. A serum free 
medium containing 2% BSA and 1µCi/ml [3H]oleate was incubated for 30 minutes at 
+37°C prior to feeding to cells. This complex was then incubated with hepatocytes for 5 
hours. [3H]acetate(10µCi/ml)  was fed to cells for 16 hours in serum free medium. 
 
To achieve LDL labeling with radioactive cholesteryl esters, 1mg of LDL (isolated from 
healthy human donors as previously described in (Havel et al., 1955)) was incubated with 
40µCi of [3H]cholesteryl oleate or cholesteryl [3H]oleate dissolved in DMSO for 2 hours 
at 40°C, followed by extensive dialysis against PBS. Cells were then incubated with these 
particles for varying times in the presence of the ACAT1 inhibitor Sandoz 58-035 
(2µg/ml) to prevent re-esterification to cholesteryl esters.  
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5.5. Lipid Extraction and Analysis 
 
Lipids were extracted from cell and tissue samples, adjusted for protein concentration, 
using organic solvents by the method by (Bligh and Dyer, 1959). The material to be ex-
tracted (cell or tissue lysates) was adjusted to 1600µl of 2% NaCl. 4ml of methanol and 
2ml chloroform was added, the sample was vortexed and centrifuged to pellet precipitated 
protein material. 2ml chloroform and 2ml water was then added, and the sample was 
again vortexed and centrifuged. After this procedure the sample was in two phases, the 
lower of which was the organic phase containing the lipids.  
 
For analyzing distribution of radioactivity in different lipid classes, the lipids were re-
solved on a regular TLC with appropriate standards, the silica scraped and radioactivity 
counted in a liquid scintillation counter. For analyzing lipid masses, a High Peroformance 
Thin Layer Chromatography (HPTLC) Camag system was used. Samples were extracted 
as above, run on a HPTLC along with appropriate standards. The plate was then stained 
with 3% copper sulfate 8% phosphorous acid solution and charred at 180°C for 5 mi-
nutes to visualize the lipids. For analysis of BODIPY-cholesterol, the plates were imaged 
under a UV-table prior to staining and burning. The amount of lipid in each lane was then 
assessed by densitometric analysis using ImageJ software. Similar mobile phases were used 
on both TLC systems: Hexane: diethyl ether: acetic acid 80:20:1 was used to separate, 
cholesteryl estrers and triglycerides from each other, petroleum ether: diethyl ether: acetic 
acid 40:60:1 was used to separate free cholesterol from other lipids in work II.  
 
Cholesterol efflux was analyzed by first labeling cells with [3H]cholesterol (1µCi/ml) 
overnight to two days. The label was then removed, and the medium replaced with fresh 
medium including or excluding cholesterol acceptors (0,2% BSA, ApoAI 10µg/ml or 
HDL2 25µg/ml). After 16-24h the radioactivity in cells and culture media was determined 
by liquid scintillation counting.  
 
To analyze detergent insolubility of sterols, cells were labeled with BODIPY-cholesterol, 
Compound 1, [3H]cholesterol or [3H]desmosterol overnight. Cells were lysed in cold 1% 
Triton-X-100, 150mM NaCl, 10mM Tris pH8.0, 1mM ethylenediaminetetraacetic acid and 
centrifuged at 16 000 x g for 30 minutes at +4° to pellet the detergent insoluble material. 
The detergent soluble material was removed and the pellet was solubilized into the same 
buffer as above. The radioactivity in insoluble and soluble samples was determined by 
liquid scintillation counting and the fluorescence with a fluorometer (Varian Cary Ec-
lipse).  
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5.6. Immunohistochemistry, Microscopy and Image Analysis 
 
To fix cultured cells and tissues, they were incubated in 4% paraformaldehyde dissolved 
in 250mM Hepes including 100µM MgCl2 and 100µM CaCl2 for 30 minutes (cell culture 
samples) or overnight (tissue samples) followed by quenching of the formaldehyde autof-
luorescence by 50mM NH4Cl. Filipin staining was performed with 0,05% filipin (Sigma) 
in 10% FBS 30 minutes at +37°C. When necessary, filipin staining was followed by incu-
bations with primary antibodies in 5% FBS 1h in +37°C and secondary antibodies in 5% 
FBS 30 minutes in +37°C. For Oil Red O (Sigma-Aldrich) staining tissue sections were 
incubated with 60% isopropanol including 0.6% Oil Red O. All samples were mounted 
using Mowiol and 1,4 diazobicyclo-(2.2.2) octane (DABCO, an antifading reagent). 
 
Imaging was performed using one of the following systems: an inverted epifluorescent 
microscope IX70 (Olympus) equipped with a Polychrome IV monochromator (TILL 
Photonics), an Olympus AX70 Provis epifluorescent system, a Leica TCS SP2 AOBS 
confocal microscope or a Zeiss LSM 5 Live confocal equipped with a line scanner for fast 
imaging. Both confocal systems and the IX70 epifluorescent system were equipped with a 
heating unit for live cell imaging. When imaged live, cells were incubated in CO2 indepen-
dent medium (Gibco). For imaging with the inverted microscopes (Olympus IX70 and 
Zeiss LSM5 Live) the cells were plated and imaged on glass bottom Ø 3,5cm dishes 
(MatTek). Time lapse sequences were acquired with the Zeiss LSM5 Live system at 
1frame/s. Image analysis was performed with Image Pro Plus software (Media Cybernet-
ics).  
 
5.7. Other Methods 
 
Proteins were determined from all samples using a DC Protein Assay from Bio Rad. 
Western Blotting was performed harvesting samples in 1% Nonidet-P40 supplemented 
with a protease inhibitor cocktail (25 ?g/ml of chymostatin, leupeptin, antipain, and peps-
tatin). 20µg of protein was then loaded to an SDS-PAGE gel of appropriate density and 
transferred to Hybond-C Extra membrane (Amersham Biosciences). The membrane was 
then blocked with 5% milk in 0,1% Tween in Tris-buffered saline for 1h at +37°C, fol-
lowed by primary antibody in the same solution overnight at +4°C and secondary antibo-
dy in 0,1% Tween in Tris-buffered saline 2 hours at room temperature. The antibodies 
were then visualized using enhanced chemiluminescence detection (ECL).  
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Results and Discussion 
 
6. BODIPY-Cholesterol as a Tool to Visualize Cholesterol in Cells and Tis-
sues 
 
6.1. Atomic Scale Computer Simulations of BODIPY-Cholesterol in Membranes 
 
As cholesterol resides within the bilayer in biological membranes, it is important to estab-
lish if a fluorescent sterol behaves similarly in a membrane compared to cholesterol. It is 
not, however, possible with current techniques to experimentally directly address interac-
tions and orientation of cholesterol or its analogues in vivo in cellular membranes. We 
therefore utilized atomic scale computer simulations to study how BODIPY-cholesterol 
(Figure 6.) behaves in a phospholipid membrane together with sphingomyelin and choles-
terol. Although computer simulations do not provide real information about the behavior 
of BODIPY-cholesterol in the membrane, they do provide a useful proxy for what hap-
pens on the atomic scale. In the simulations, BODIPY-cholesterol occupies a similar area 
on the membrane compared to cholesterol, does not affect membrane thickness and only 
minimally perturbs neighboring lipids. Importantly, the simulations also show that the 
sterol back bone of BODIPY-cholesterol is positioned similarly to that of cholesterol so 
that the BODIPY-group most of the time points toward the inside of the membrane, the 
sterol back bone residing upright and the OH-group on the same level as it is for choles-
terol (I, Figure 1 and Supporting Information). 
 
Figure 6. Structure of BODIPY-cholesterol 
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6.2. Biochemichal Charasteristics of BODIPY-Cholesterol 
 
Next, we analyzed the biochemical behavior of BODIPY-cholesterol in living cells to ad-
dress if the behavior of BODIPY-cholesterol in cells is similar to that of cholesterol. We 
utilized either wild type CHO cells or CHO cells lacking a functional NPC1 protein (M12-
cells). The cells were incubated with 0.5µM BODIPY-cholesterol overnight. Use of this 
protocol resulted in bright labeling of cells, with only ~1% addition of sterol to the total 
cellular sterol pool (I, Figure 2A). This is important, as we did not want to load cells with 
sterol and because high levels of the unnatural sterol might interfere with cellular func-
tions. Additionally, no metabolism of the probe could be detected during this time, as 
assessed by TLC (not shown), implicating that what was seen by microscopy was intact 
BODIPY-cholesterol. To test if BODIPY-cholesterol could substitute for cholesterol in 
living cells with no other source of sterol, we utilized a CHO cell line called M19. These 
cells do not synthesize any sterols and are unable to survive without exogenously added 
cholesterol (Hasan et al., 1994). We cultured these cells in 5% LPDS and 35µM oleate and 
supplemented the medium with 1µM sterol: cholesterol, BODIPY-cholesterol or DHE or 
only DMSO and assessed their growth by determining the amount of protein in each 
sample. The control cells with no supplementation slowed down their growth after a day 
in culture, as their cholesterol stores were depleted, whereas all supplemented cells kept 
growing with no significant differences between sterols supplemented (I Figure 2B). This 
experiment suggests that BODIPY-cholesterol is able to support cell growth. 
 
Next, to address if BODIPY-cholesterol behaves biochemically similarly to cholesterol, 
we labeled cells with both BODIPY-cholesterol and [3H]cholesterol overnight and com-
pared their behavior. When the postnuclear supernatant was subjected to sucrose density 
gradient ultracentrifugation as in (Hao et al., 2002), BODIPY-cholesterol and 
[3H]cholesterol separated very similarly with no significant differences in their appearance 
on different sucrose densities, implicating that the subcellular distribution of BODIPY-
cholesterol is similar to that of [3H]cholesterol (I Figure 2C).  
 
Resistance of biological membranes and their constituents to the detergent extraction at 
+4° is one of the fundamental characteristics of cholesterol in biological membranes and 
is often used as a proxy for rafts. We next tested if BODIPY-cholesterol is found in de-
tergent resistant membranes. When compared to [3H]cholesterol, BODIPY-cholesterol 
was resistant to detergent extraction similarly to cholesterol (I Figure 2D). We also tested 
two other sterols for their detergent resistance in this assay. [3H]desmosterol, previously 
shown to be slightly less detergent resistant (Vainio et al., 2006) was also slightly less de-
tergent resistant in this experiment. Another BODIPY-derivative of cholesterol where the 
BODIPY is joined to the sterol nucleus with an ester linkage (Compound 1)  was almost 
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completely detergent soluble in line with results from an earlier study (Li et al., 2006). In 
addition, when M12 cells were used, the detergent insolubility of both [3H]cholesterol and 
BODIPY-cholesterol was increased, consistent with earlier results showing more deter-
gent resistant cholesterol in NPC1 deficient cells (Lusa et al., 2001).  
 
Effluxing and esterifying cholesterol are the two principal ways for cells to lower their 
sterol levels. We therefore tested if these reactions would occur also for BODIPY-
cholesterol. WT CHO and M12 cells labeled two days with both BODIPY- and 
[3H]cholesterol were incubated in serum free medium in the presence or absence of phy-
siological cholesterol acceptors (0,2% BSA or 10µg/ml ApoAI) for an additional 24 hours 
and the fluorescence and radioactivity in cells and culture medium were determined to 
calculate the fraction effluxed. In these experiments, cells effluxed BODIPY-cholesterol 
much more avidly than they do [3H]cholesterol (I Figure 2E). However, the highest efflux 
rates were to the specific acceptor ApoAI. In addition the defect in cholesterol efflux seen 
in NPC1 deficient cells (Chen et al., 2001) can also be seen with BODIPY-cholesterol 
indicating that although higher than for natural cholesterol, efflux of BODIPY-
cholesterol still follows physiological regulation.  
 
To test if cells are able to esterify BODIPY-cholesterol we used a mouse macrophage cell 
line RAW264.7 as these cells esterify large amounts of cholesterol, especially when chal-
lenged by LDL loading. The cells were labeled with BODIPY- or [3H]cholesterol over-
night in the presence or absence of 10µg/ml acetylated LDL, the lipids were extracted and 
separated by TLC. However, only a small amount of BODIPY-cholesterol was found in 
esterified form (I Figure 2F). It is possible that the BODIPY-group inhibits the reaction 
catalyzed by ACAT1 or that the cells prefer to efflux BODIPY-cholesterol or store it un-
esterified in lipid droplets (Jansen et al., 2010).  
 
Together, these results show that some of the biochemistry of BODIPY-cholesterol fol-
lows that of [3H]cholesterol, while in some aspects BODIPY-cholesterol behaves diffe-
rently. This biochemical characterization is important as fluorescent probes always differ 
from their natural counterparts. It is therefore essential to know which aspects are compa-
rable and in which aspects one needs to be cautious when making conclusions.  
 
6.3. BODIPY-Cholesterol Imaging in Living Cells and Organisms 
 
To study the localization and behavior of BODIPY-cholesterol in living cells and organ-
isms, we labeled cells with the probe and studied them under the microscope. First we 
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Another feature of NPC cells is that motility of endosomes is hampered (Ko et al., 2001). 
The precise reason for this phenomenon is not known, but it is considered to be a sec-
ondary defect of endosomal cholesterol accumulation as Rab proteins (Lebrand et al., 
2002) and SNAREs (Fraldi et al., 2010) become trapped in high cholesterol membranes. 
When the motility of BODIPY-cholesterol containing organelles was quantified in WT 
CHO and M12 cells we observed a defect in NPC1 deficient cells also with BODIPY-
cholesterol (I Figure 3C). This result for the first time demonstrates the motility of sterol 
containing organelles and confirms impaired motility of cholesterol containing organelles 
in NPC1 deficient cells. To study sterol exchange between cells we cocultured rhodamine-
dextran labeled WT CHO cells with non-rhodamine-dextran labeled M12 cells and labeled 
the coculture with BODIPY-cholesterol from DMSO overnight. Initially BODIPY-
cholesterol intensity in both cell types was similar, but when chased, M12 cells started to 
accumulate more BODIPY-cholesterol where as BODIPY-cholesterol intensity in WT 
CHO cells decreased (I Figure 4A). To more precisely quantify how this shuffling be-
tween cells happened, we cocultured BODIPY-cholesterol and rhodamine-dextran la-
beled WT CHO or M12 cells with unlabeled CHO or M12 cells. During the first hours of 
coculture BODIPY-cholesterol started to appear in the non-labeled cell population and 
after 24 of coculture, BODIPY-cholesterol was spread between the two cell populations 
(I Figure 4B). However, M12 cells acquired more of the sterol independent of if they were 
donors or acceptors. These results demonstrate that cells in culture can and do exchange 
sterol between them and balance out sterol levels. It also demonstrates that NPC1 defi-
cient cells collect more cholesterol, and when cocultured with WT cells always end up 
with more sterol, presumably due to their lower ability to efflux cholesterol to the culture 
medium (I Figure 2E). 
 
Next we labeled mouse embryonic brain cell culture with BODIPY-cholesterol, again 
from DMSO overnight. These cultured were obtained from hippocampi of E17½ mouse 
embryos. In such cultures, most of the BODIPY-cholesterol partitioned into neurons (I 
Figure 4C). To verify that this result was not due to the use of BODIPY-cholesterol we 
repeated the experiment and stained the cells with filipin. Indeed, also filipin stains neu-
rons more brightly than astrocytes (I Figure 4D). Finally, to demonstrate the partitioning 
of BODIPY-cholesterol in a living organism, we injected fertilized zebra fish embryos at 
one- to two-cell stage with 20-40 nmol BODIPY-cholesterol or FITC-BSA (0.8-1.5pmol 
per embryo) and followed the development of the embryo until 7 days post fertilization. 
Importantly, the fish developed normally in the presence of BODIPY-cholesterol and no 
toxic effects were seen. BODIPY-cholesterol was gradually mobilized from the yolk sack 
and incorporated into organs known to contain large amounts of cholesterol such as the 
gut and the central nervous system, whereas the FITC-BSA disappeared within 7 days (I 
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Figure 5). These results demonstrate that BODIPY-cholesterol can be used to visualize 
sterol compartmentalization and trafficking also in living organisms.  
 
This study provides a new tool for visualizing sterol trafficking in living systems. While 
previous fluorescent sterol probes either have weak fluorescent properties or behave very 
differently from natural cholesterol, BODIPY-cholesterol is both bright and mimics cho-
lesterol in many aspects. As with any fluorescent probe, one needs to keep in mind that a 
probe never behaves exactly like its natural model. With this in mind, BODIPY-
cholesterol can be used to study the cell biology and physiology of cholesterol in living 
cells and organisms. 
 
7. Triglycerides in Niemann-Pick Type C Disease 
 
7.1. NPC1 Single Nucleotide Polymorphisms (SNPs) Associate with Altered Trig-
lyceride Levels in Man 
 
The initial hypothesis of this study was that variations in the NPC1 gene would be asso-
ciated with altered cholesterol levels in serum at the population level. Since NPC1 binds 
cholesterol and its deficiency causes a cholesterol storage disease, we thought it probable 
that its genetic variations could affect circulating lipids. This hypothesis was tested first 
with 19 NPC1 SNPs in a population cohort of Swedish men involved in the Uppsala 
Longitudinal Study of Adult Men (ULSAM) (Hedstrand, 1975; Zethelius et al., 2005) con-
sisting of 1053 individuals. To our surprise, there were only weak associations between 
NPC1 genotype and plasma cholesterol levels. Instead, there were several SNPs strongly 
associated with altered triglyceride levels (II Table). To further validate this unexpected 
result, we tested the SNP that gave the most significant p-value in the ULSAM cohort 
(rs1429934) in two additional cohorts; 2882 individuals from The Framingham and Fast 
Revascularization During Instability in Coronary Artery Disease II (FRISCII) (Investiga-
tors, 1999) and the Sweden Women and Men and Ischemic Heart Disease (SWISCH) 
(Johnston et al., 2004) studies, and 5159 men participating in the Malmö Diet and Cancer 
Study (MDC) Cardiovascular Cohort (Berglund et al., 1993). The result was confirmed as 
the SNP was associated with increased triglyceride levels also in these additional popula-
tion cohorts (II Supplementary Table III). This suggests that genetic variations in NPC1 
are indeed one of the determinants for circulating triglyceride levels on the population 
level.  
 
 7.2. Lipid Balance in Npc1
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exhibited a massive increase in free cholesterol levels, but also a significant decrease in 
triglyceride levels, as analyzed by HPTLC (II Figure 2A) and seen by filipin stainig (Figure 
8). In addition, when the culture media of these cells was analyzed, we noted an increase 
in free cholesterol secretion, but a decrease in the secretion of triglycerides. As previously 
published (Kulinski and Vance, 2007), these cells secreted more ApoB, as assessed by 
western blotting (II Figure 2A). To test if the lipid and ApoB found in the culture media 
were associated with secreted VLDL particles, the medium was subjected to a sucrose 
density gradient fractionation to separate VLDL particles (Asp et al., 2000). In these gra-
dients we found 98% of lipid and 60% of apoB floating on top of the gradient, indicating 
that the majority of lipid and apoB was associated with VLDL particles. To study if these 
changes in hepatic lipid balance are also reflected in circulating lipid levels we analyzed 
lipids in the serum of Npc1+/+ and Npc1-/- mice as previously described (Jaari et al., 
2001).  Indeed, we also found increased total cholesterol, but decreased triglyceride levels 
in the serum of the Npc1-/- mice (II Figure 2B). Together, these results demonstrate a 
severe dysregulation of neutral lipids in the Npc1-/- mouse.  
 
7.3. Fatty Acid Metabolism in Npc1-/- Hepatocytes 
 
NPC1 has been suggested to function as an endosomal fatty acid transporter due to its 
homology with bacterial RND permeases (Davies et al., 2000). This theory, if correct, 
could help us explain the decreased neutral lipid storage in the Npc1-/- hepatocytes as the 
fatty acid not able to leave endosomes would not be able to reach the ER to be esterified 
to form triglycerides. We therefore labeled LDL particles with cholesteryl [3H]oleate, i.e. a 
cholesterol ester molecule with the radioactive atoms in the fatty acid part of the mole-
cule. These particles were fed to Npc1+/+ and Npc1-/- hepatocytes in serum free medium 
for 3 hours, and chased for an additional 3 hours, during which time the cells start to hy-
drolyze the cholesteryl [3H]oleate to yield free cholesterol and [3H]oleate and metabolize 
them further. The distribution of the radioactivity in different lipid classes was then ana-
lyzed by extracting lipids, separating them on TLC and counting radioactivity in each lipid 
class. The Npc1-/- cells were slightly slower in hydrolyzing the esters with 68%±1.8% 
hydrolyzed after the three hour chase in Npc1-/- cells and 82%±3.5% hydrolyzed in 
Npc1+/+ cells. However, in both genotypes, the vast majority of the released fatty acid 
became incorporated in triglyceride (II Figure 3A).  In order to be incorporated into trig-
lyceride, the fatty acid must leave the endosome and traffic to the ER as this is where the 
triglyceride synthesizing enzymes acyl-CoA:monoacylglycerol acyltransferase (MGAT) and 
acyl-CoA:diacylglycerol acyltransferase (DGAT) reside (Yen et al., 2002; Kuerschner et al., 
2008). Our data therefore indicate that the cholesteryl ester-derived fatty acid is not 
trapped in endosomes in Npc1-/- hepatocytes. This is in accordance with previous results 
from NPC1 deficient fibroblasts (Passeggio and Liscum, 2005). However, there was a 
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small but significant decrease in the incorporation of the LDL-derived fatty acid into trig-
lyceride, possibly contributing to the decrease in triglyceride levels. In addition, there was 
an increase in the amount of radioactivity discovered in free fatty acid in Npc1-/- hepato-
cytes, consistent with the increased free fatty acid levels reported in NPC liver endosomes 
(Chen et al., 2005a).  
 
As we did not detect a defect in how Npc1-/- hepatocytes handle endosome-derived fatty 
acids, we next tested if the metabolism of free [3H]oleate complexed to albumin was dif-
ferent between the genotypes. This is the major pathway of lipid entry to the liver during 
fasting. The hepatocytes were incubated in serum free medium supplemented with 
[3H]oleate-BSA for 5 hours, and the distribution of radioactivity between lipid classes was 
analyzed. Most radioactivity was found in triglyceride in both cell types (II Figure 3B). 
However, a significant decrease was again seen in triglyceride synthesis in Npc1-/- cells.  
 
These experiments suggested that there was no severe defect in how Npc1-/- cells handled 
the incoming fatty acid, but rather that the decrease in triglyceride was due to a more sub-
tle regulation of triglyceride synthesis. We therefore studied triglyceride synthesis from its 
core building block acetate. To this end, Npc1+/+ and Npc1-/- hepatocytes were cultured 
in the presence of [3H]acetate for 16 hours in serum free medium and the incorporation 
of radioactivity to different lipid classes was analyzed as described above. Indeed, there 
was a large decrease in the incorporation of [3H]acetate into triglyceride in Npc1-/- cells 
(II Figure 3C). In parallel there was an increase in the incorporation of [3H]acetate into 
cholesterol and to choline phospholipids. This increase in carbon unit flux to cholesterol 
synthesis was evident also from [3H]oleate (II Figure 3B) and cholesteryl [3H]oleate (II 
Figure 3A). For fatty acid-derived carbon to end up in free cholesterol, the fatty acid has 
to be degraded in beta oxidation to yield Acetyl Coenzyme A which can then serve as a 
building block for cholesterol biosynthesis.  
 
Finally, to test if Npc1-/- cells have the capacity to synthesize triglyceride in the presence 
of ample exogenous substrate, we incubated Npc1+/+ and Npc1-/- hepatocytes with 
500µM oleate-BSA complex. After 16 hour incubation with exogenous fatty acids, the 
triglyceride levels were determined by HPTLC. We found similar triglyceride levels in 
both genotypes, indicating no fundamental defect in the triglyceride or lipid droplet ma-
chinery in Npc1-/- cells (II Figure 4). However, when the exogenous fatty acid was re-
moved, Npc1-/- cells immediately ceased synthesizing more triglyceride, unlike cells from 
their Npc1+/+ littermates. Together, these experiments indicate that Npc1-/- cells have a 
decreased triglyceride synthesis that is not due to a defect in fatty acid transport nor to the 
triglyceride synthesis machinery. Rather, as the decreased carbon flux to triglyceride is 
paralleled with an increased carbon flux to cholesterol synthesis, these data suggest that 
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the metabolic flux of carbon units is guided towards cholesterol at the expense of triglyce-
ride.  
7.3. Inhibition of Cholesterol Synthesis Corrects the Triglyceride Reduction in 
Npc1-/- Hepatocytes 
 
If indeed the increased cholesterol synthesis was the explanation for low triglyceride levels 
in the Npc1-/- liver, then blocking cholesterol synthesis should normalize triglyceride le-
vels in Npc1-/- cells. Npc1+/+ and Npc1-/- hepatocytes were therefore incubated with 
20µM lovastatin and 50µM mevalonate (to support cell viability) for 16 hours, and lipid 
masses were determined by HPTLC. This treatment reduced cholesterol amounts in both 
genotypes, but increased triglyceride levels in Npc1-/- hepatocytes (II Figure 5A). Incuba-
tion with statin increased the secretion of triglyceride from Npc1-/- hepatocytes, whereas 
the effect in Npc1+/+ hepatocytes was the opposite (II Figure 5B).  In addition, when 
Npc1-/- cells incubated with exogenous free fatty acid were treated with statin, they kept 
synthesizing more triglyceride after the exogenous fatty acid was removed, similarly as the 
Npc1+/+ cells (II Figure 4). These results further support the idea of the highly increased 
cholesterol synthesis in Npc1-/- cells being responsible for the decreased triglyceride le-
vels. When the synthesis of cholesterol is blocked with statin, the carbon that would have 
been used to produce more and more cholesterol can now be used for triglyceride synthe-
sis. 
 
Interestingly, while this work was underway and after its publication, additional reports 
have linked NPC1 function to neutral lipid balance. Triglycerides were found to be in-
creased in a subset of NPC patients (Garver et al., 2010), Npc1 haploinsufficiency 
(=heterozygocity) was found to promote weight gain (Jelinek et al., 2010) and a NPC1 
SNP was found to be associated with early onset and morbid obesity in humans (Meyre et 
al., 2009). The SNP found associated with morbid obesity was also tested in our initial 
screen with 19 NPC1 SNPs (rs1805081 II Table). We found no associations for circulat-
ing lipid levels nor to obesity (data not shown) with this SNP. This is not surprising, as 
the amount of the morbidly obese in this data set was very small. These studies together 
with our work open new possibilities for NPC1 functions in cells. Does NPC1 have a 
direct regulation of neutral lipid balance, and is the NPC disease affected by this pheno-
menon, will be the subject of further research. 
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8. ORP1L Function in Endosomal Trafficking and Function 
 
8.1. Sterol Binding by ORP1L 
 
Previously, ORP1L has been shown to bind 22(R) – and 25-hydroxycholesterol (OHC) 
(Suchanek et al., 2007; Yan et al., 2007). We first wanted to characterize the sterol binding 
specificity of ORP1L more comprehensively. For this, ORP1L-GST was produced in an 
E. Coli expression system, and the protein was purified. The ability of the purified protein 
to bind oxysterols was tested on an in vitro charcoal-dextran based assay. ORP1L was first 
bound to [3H]25-OHC, a known ORP1L ligand, and this binding was competed with dif-
ferent oxysterols. 7-ketocholesterol, 22(R)OHC, 24(S)OHC and 25OHC were all able to 
compete out the [3H]25-OHC, indicating that ORP1L is able to bind all of these oxyste-
rols with roughly equal efficiencies (III Figure 1A). Many ORPs are also able to bind cho-
lesterol, and ORP1L has also been suggested to do so (Suchanek et al., 2007). We there-
fore tested if we could demonstrate this binding in vitro. As cholesterol is more poorly 
soluble in water than its oxidized forms, this experiment was done on large unilamellar 
vesicles (LUV). In such experiments [3H]cholesterol is placed into the vesicle, from which 
a cholesterol binding protein should be able to extract it. However, GST-ORP1L cannot 
be produced without the use of detergent, the presence of which would collapse the 
LUVs. Therefore we used the shorter splice variant of ORP1, ORP1S to perform these 
experiments, as ORP1S can be produced without detergent and the sterol binding pocket 
in the two variants is identical. Indeed, we were able to show binding of cholesterol to 
ORP1 as efficiently as published earlier for ORP2 (Hynynen et al., 2009)  (III Figure 1B).  
 
To further study the sterol binding of ORP1L, and how its sterol binding state affects 
cells, we generated a mutant of ORP1L possibly unable to bind oxysterols. By homology 
modeling of the ORP1L sterol binding pocket we deduced that amino acids 560-563 
(ELSK) would localize to the lid of the sterol binding pocket and that deletion of these 
amino acids would render the protein unable to bind sterols (III Figure 1C). We found 
that the ?560-563 binds significantly lower to 22(R), 24(S) and 25-hydroxycholesterols 
indicating that this mutant is indeed defective in sterol binding.  
 
8.2. Endosomal Functions by ORP1L 
 
To study how the defect in ORP1L sterol binding affects its behavior in cells, we overex-
pressed a Green Fluorescent Protein (GFP) fusion construct of this mutant in HeLa cells 
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and compared its localization to WT ORP1L-GFP. WT ORP1L overexpression creates 
large perinuclear clusters of late endosomes where it is able to recruit its binding partner 
Rab7 (Johansson et al., 2005). In contrast, the ?560-563 ORP1L was found in smaller 
endosomes dispersed throughout the cell (III Figure 2Ba, d and g). A similar result was 
recently achieved by expressing an ORP1L mutant with the whole ORD deleted (Rocha 
et al., 2009). The localization of WT ORP1L containing organelles has been linked to in-
creased recruitment of dynein-dynactin motor complex driving the motility of endosomes 
toward the center of the cell (Johansson et al., 2007). To investigate if also the mutant 
ORP1L localized to late endosomes, the cells were costained for the Early Endosomal 
Antigen-1 (EEA1) or  Lysosome Associated Membrane Protein 1 (LAMP1) to visualize 
early endosomes and late endosomes and lysosomes, respectively. As seen in the case of 
WT ORP1L, the ?560-563 mutant showed no colocalizations with EEA1 (III Figure 2B 
d-f), but partial colocalization with LAMP1 (III Figure 2B g-i). In addition, both con-
structs colocalized extensively with Rab7 (III Figure 2A and B a-c), indicating that despite 
the different morphology, the ORP1L containing organelles were still late endosomes. 
Similar results with perinuclear WT ORP1L and scattered ?560-563 ORP1L that partially 
colocalized with LAMP1 were observed when the constructs were expressed in a mouse 
macrophage cell line RAW264.7 (III Figure S1).  
 
To test if the sterol binding affects the functions of ORP1L, we tested if ?560-563 
ORP1L is also capable of binding Rab7. Both WT ORP1L and ?560-563 mutants coim-
munoprecipitate equally well with Rab7, indicating that the ability of ORP1L to interact 
with Rab7 is not dependent on its sterol binding capacity (III Figure 2D). ORP1L also 
binds to the ER resident VAPs. This binding is mediated throught the FFAT motif and 
can be abolished by mutating this domain. When the ?560-563 ORP1L was mutated also 
in its FFAT motif, the scattering phenotype disappeared and instead ORP1L was found 
again on perinuclear clusters, indicating that ER association via binding to VAP is the 
force holding the organelles in their peripheral location (III Figure 2C).  
 
As the peripheral localization of the WT ORP1L organelles is considered to be due to 
increased recruitment of dynein (Johansson et al., 2007), we tested if the more peripheral 
localization of ?560-563 ORP1L containing organelles was caused by a defect in recruit-
ing dynein, despite the ability of the mutant to bind Rab7. This was tested by staining cells 
with antibodies against the dynein subunit P150glued.  This staining is mostly diffuse cyto-
solic in control cells but in both WT and ?560-563 ORP1L the staining was clearly punc-
tuate, colocalizing with ORP1L (III Figure 3A). This indicates that the sterol binding abili-
ty of ORP1L does not affect its association with dynein. As ?560-563 ORP1L had clearly 
more peripheral (and thus not dynein-driven) localization, we tested if also other motor 
types would be recruited with ORP1L overexpression to explain the altered localization. 
Indeed, also a late endosomal microtubule plus end directed motor Kinesin-2 was similar-
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ly recruited to ORP1L containing organelles of both WT and ?560-563 ORP1L as judged 
by staining the cells with antibodies against the Kinesin-2 subunit KIF3A (III Figure 3b). 
These data suggest that ORP1L and its sterol binding status could be one of factors regu-
lating the directionality of endosomal movement. 
 
To more precisely assess how ORP1L affects motility of late endosomes, we overex-
pressed both WT ORP1L-GFP and ?560-563 ORP1L-GFP in HeLa cells. The cells were 
labeled with Alexa 568 dextran overnight in order to visualize the movement of late endo-
somes and lysosomes. The cells were then imaged live to determine the motility of these 
organelles. Organelles containing ORP1L-GFP exerted very little motility. This was par-
ticularly clear for the large clusters of endosomes seen in WT ORP1L-GFP overexpress-
ing cells, but also for the ?560-563 ORP1L-GFP (III Figure 4A, green bars). The coloca-
lization between ORP1L-GFP and dextran was poor, indicating that the endocytosed dex-
tran did not reach the WT ORP1L or ?560-563 ORP1L containing organelles efficiently. 
There were, however, several instances where a dextran-positive organelle could be seen 
on the surface of an ORP1L containing organelle (III Figure 4C) and moving along with 
it, without fusing with it. When the ?560-563 mFFAT ORP1L double mutant was simi-
larly expressed, all of the dextran became associated with the ORP1L-GFP containing 
clusters, with no dextran-positive organelles remaining free of ORP1L. How this “at-
tachment” of endolysosomes to ORP1L containing organelles takes place, is so far un-
known.  
 
The motility of dextran positive organelles was also decreased in all of the ORP1L over-
expressing cells compared to cells expressing GFP only (III Figure 4A red bars). This is 
partly because of their attachment to the ORP1L containing organelles, but also because 
the motility of the “free” dextran organelles was also decreased. This might be because 
there is still ORP1L-GFP on these organelles, although below detection limit, or because 
a large amount of the vesicle movement machineries (e.g. motor proteins) are being re-
cruited to the ORP1L containing endosomes thus reducing their availability to other or-
ganelles. When the double mutant ?560-563 mFFAT ORP1L was expressed in a similar 
setup, we again saw clusters of endosomes that exerted very little motility. However, when 
the mFFAT ORP1L was expressed alone, the motility of ORP1L containing organelles 
was significantly higher than with WT or the other mutants. Their motility also resembled 
that of regular late endosomes with typical back-and forth movements and longer vectori-
al movements. These organelles also colocalized with the endocytosed dextran, possibly 
due to their increased motility and increased communication with other endosomes.  
 
As the overexpression of ORP1L or its mutant forms decreased the motility of endo-
somes, we next tested if its depletion by siRNA would have an effect on endosomal mo-
tility. We transfected HeLa cells with RNA sequences against ORP1 or with a non-
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specific RNA sequence (control). This method resulted in a 75-80% decrease in the levels 
of ORP1L (III Figure 5A). The cells were again labeled with Alexa 568 dextran overnight 
to label late endosomes and lysosomes and imaged live. The motility of dextran contain-
ing organelles was indeed increased when ORP1L was removed from the cells (III Figure 
5B). This is an opposite result from the overexpression studies indicating that ORP1L has 
a true effect on endosome motility, inhibiting the motility of organelles it is associated 
with. In addition to the extent of motility, also the quality was different, as more peripher-
al organelles were seen in the ORP1 knock down condition (III Figure 5C), consistent 
with the more distributed location reported earlier (Johansson et al., 2007).  
 
To test if the altered localization and motility also affects the degradative function of en-
dosomes, we asked whether the ORP1L overexpressing or silenced cells were still capable 
of degrading epidermal growth factor (EGF). EGF is normally degraded in lysosomes and 
fluorescently labeled EGF provides a simple means to study the integrity of the endocytic 
system. This was assessed by feeding cells with rhodamine-labeled EGF and chasing 
them. Control cells degrade EGF in hours, which can be seen as disappearance of fluo-
rescence from cells. WT ORP1L and ?560-563 ORP1L overexpressing cells had a severe 
defect in EGF degradation, probably due to the decreased motility and communication of 
endosomes (III Figure 6A). EGF was able to reach LAMP1 positive organelles also when 
ORP1L was expressed (III Figure S3), but EGF, like dextran did not reach the ORP1L 
containing endosomes (III Figure 6C-E). ORP1 silencing, however, had no effect on 
EGF degradation (III Figure 6B) suggesting that the highly moving endosomes in ORP1 
depleted cells are functional. 
 
Together, these results indicate that ORP1L functions in the regulation of motility and 
localization of endolysosomes. ORP1L stalls the motility of these organelles probably by 
binding to VAP, and this leads to functional defects in endo-lysosomes when ORP1L is 
overexpressed.  
 
8.3. ORP1L in Macrophages 
 
To analyze the consequences of ORP1L silencing in a more physiological setup, we used 
RAW264.7 macrophages as ORP1L is highly induced when monocytes differentiate into 
macrophages (Johansson et al., 2003). Earlier it was found that overexpression of ORP1L 
in bone marrow-derived macrophages enhances atherosclerotic lesion formation  appar-
ently by reducing cholesterol efflux to HDL (Yan et al., 2007). We therefore generated 
two cell lines stably expressing shRNA constructs containing a non-targeting or ORP1 
targeting sequences. This method yielded a ~75% decrease in both ORP1L mRNA (not 
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shown) and protein (III Figure 7A) levels. We first determined if this manipulation affects 
endosome motility. We used acLDL fluorescently labeled with a DiI probe to track the 
movement of endosomes and, furthermore, to track the organelles specifically involved in 
cholesterol handling. We assessed the motility of the organelles by a method where se-
quential frames are subtracted from one another leaving only organelles that moved dur-
ing the video. We found that the DiI containing organelles moved faster in the cells where 
ORP1 was depleted (III Figure 7A).  
 
To test whether depletion of ORP1L and the increased motility of cholesterol containing 
organelles affects cholesterol in these cells, we labeled the cells with acLDL containing 
[3H]cholesteryl oleate. Efflux of [3H]cholesterol was then followed to two different physi-
ologic acceptors: lipid-poor ApoAI and spherical HDL. We found that efflux to ApoAI 
was severely impaired in cells depleted of ORP1L, but efflux to HDL was not (III Figure 
7B). As different cellular proteins are responsible for efflux to these acceptors, the results 
suggest that the one responsible for efflux to ApoAI, i.e. ABCA1 protein, is not function-
ing properly in cells lacking ORP1L. No changes were observed in the uptake of the 
probe, or in the hydrolysis of the cholesteryl ester molecule (data not shown). The differ-
ence was also only seen when cholesterol was internalized in acLDL, and not when cells 
were labeled with free [3H]cholesterol. This result indicates that the efflux problem is spe-
cific to endosomal, lipoprotein-derived cholesterol, which makes sense since ORP1L is an 
endosomal protein.  
 
The results of this work implicate that ORP1L regulates the motility and localization of 
endolysosomes depending on its sterol binding status. A recent work using ORP1L lack-
ing the entire ORD domain found that sterols regulate endosomal localization such, that 
endosomes loaded with cholesterol are found close to the nucleus (Rocha et al., 2009). 
This pattern in localization was reversed when truncated ORP1L mutant was expressed, 
indicating that ORP1L sterol binding is needed for this phenomenon. Rocha et al sug-
gested a model where sterol free ORP1L is bound to VAP on the ER and sterol binding 
to ORP1L replaces VAP with the dynein motor complex and endosomes are transported 
to the perinuclear area (Rocha et al., 2009). The present work, together with previous stu-
dies (Johansson et al., 2007; Rocha et al., 2009), suggests that endolysosomal localization 
and motility is regulated by ORP1L and its sterol binding status. When ORP1L is sterol 
free, it binds to VAP proteins on the ER and inhibits the motility of these organelles. 
When cholesterol levels in cells increase, ORP1L binds cholesterol (or one of the oxyste-
rols), detaches from VAP and the motility of these organelles is released. Both processes 
are needed for proper handling of cholesterol in endosomes since both ORP1L overex-
pression (Yan et al., 2007) and silencing (this study) perturbs cholesterol efflux.  
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Conclusions and Future Prospects 
 
This work describes the effects of two endosomal sterol binding proteins, ORP1L and 
NPC1 on endosomal transport and lipid metabolism. These studies suggest that choles-
terol and endosomal cholesterol binding proteins have a crucial role in regulating endo-
somal movement, but also more generally in lipid metabolism. These effects are mediated 
at least by NPC1 and ORP1L, but possibly also by other endosomal sterol binding pro-
teins, such as MLN64 (Hölttä-Vuori et al., 2005) or NPC2. In addition, this study pro-
vides a new tool, BODIPY-cholesterol, for studying cholesterol in living cells and tissues. 
 
I) BODIPY-cholesterol mimics cholesterol on cellular membranes and can be used to 
study in cholesterol trafficking. BODIPY-cholesterol is an important new tool for lipid 
cell biology and will help elucidate new aspects of sterol trafficking (as already observed in 
(Jansen et al., 2010)). BODIPY-cholesterol may greatly help scientists to unravel new as-
pects of cholesterol in cells, but the imaging of cholesterol and other lipids is continually 
improving. First, the only physiological way for cholesterol to enter cells is from lipo-
protein particles. However, BODIPY-cholesterol can be esterified to a fatty acid creating 
BODIPY-cholesteryl esters. These molecules can then be incorporated into LDL particles 
and fed to cells in a physiological manner. Importantly, this allows one to specifically fol-
low the trafficking of LDL-derived cholesterol (Uronen et al manuscript in preparation). 
Also other ways to develop the methodology of BODIPY-cholesterol can be thought of, 
such as oxidized forms of BODIPY-cholesterol to study oxysterol trafficking or using 
BODIPY-cholesterol to visualize sterol trafficking in live mammals. In the long haul 
however, it would be attractive to develop techniques, that would enable one to visualize 
cholesterol itself, without using fluorescent analogs or sterol binding compounds (Lim et 
al., 2010).  
 
II) NPC1 genetic status was found to be associated with changes in triglyceride balance in 
both mice and men. Several NPC1 SNPs were associated with increased triglyceride levels 
in man, and the NPC1 deficient mouse had decreased triglyceride levels as a result of de-
creased triglyceride synthesis. This work, together with other recent finginds in the field 
(Meyre et al., 2009; Garver et al., 2010; Jelinek et al., 2010) provide a new participant to 
triglyceride metabolism and obesity. How does this endosomal cholesterol binding pro-
tein affect how the body handles and stores triglycerides? The data presented in this thesis 
supports a view where NPC1 regulates changes in cholesterol metabolism, which then 
lead to changes in triglyceride metabolism. The integration of cholesterol and triglyceride 
metabolism is not fully understood, but does involve e.g. the LXR-SREBP1c pathway.  
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III) ORP1L functions as sterol dependent regulator of endosome motility and localiza-
tion. In this study, we showed that ORP1L has a negative effect on endosome motility 
dependent on its ability to bind VAP, and that the localization of endosomes is dependent 
on the ability of ORP1L to bind sterols. We also provide evidence that ORP1L changes 
the functional status of endo-lysosomes. An interesting aspect of ORP1L, regarding fu-
ture studies, is that in addition to differentiated macrophages it is also highly expressed in 
the central nervous system (Johansson et al., 2003). The present study brings more insight 
into this since the brain-specific sterol 24(S)OHC (Lutjohann et al., 1996) seems to be the 
best of the tested ligands for ORP1L. It is tempting to speculate therefore, that ORP1L 
might have a role in sterol regulated transport of endosomes in neurons. 
 
Integrating knowledge from cell biology and lipid metabolism is of outstanding impor-
tance when we try to understand the mechanisms of common metabolic diseases. The 
studies presented in this work provide two models of endosomal sterol binding proteins 
affecting phenomena important in such states. The NPC1 protein has a surprising role in 
triglyceride metabolism and obesity, and the ORP1L protein may regulate cholesterol ef-
flux from foam cells via endo-lysosomal dynamics. To gain further insight into the me-
chanisms of metabolic diseases, one must understand the mechanisms governing the cell 
biological processes behind them.  
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